Clinical trial

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#Antibodies #Biotherapeutics #Clinical trial

IONTAS collaboration with F-star enters clinical trial

F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of… Read More

#News

#Clinical trial #Diabetes

New clinical potential for treating diabetes

Scohia has presented the results of a Phase I clinical trial for SCO-267, an orally bioavailable GPR40 full agonist, at the Virtual Scientific Sessions of the American Diabetes Association. Free fatty acid receptor 1 (GPR40) is a G protein-coupled receptor expressed in pancreatic islet and enteroendocrine cells, and SCO-267 is… Read More

#News

#Clinical trial #Diabetes #Drug development #GlobalData #Type 2 diabetes

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide… Read More

#News #Trends & Analysis

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#Clinical trial #Covid-19 #Drug development

Covid-19 patients with sepsis one step closer to life-saving treatment

A clinical trial has begun using a human protein called Annexin A5, which is being studied as a potential therapy for Covid-19 patients with sepsis. Annexin A5 is a protein produced inside the human body with unique anti-coagulation (preventing blood clots) and anti-inflammatory properties that could help in the fight… Read More

#News

#Clinical trial #Gastroenterology #Irritable Bowel Syndrome #Pharma

4D pharma new data for treatment of irritable bowel syndrome

4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn… Read More

#News

#Clinical research #Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Positive interim Phase II results for GSK Medicago Covid-19 vaccine

Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More

#Covid-19 #News

#Alzheimer's #Clinical trial #Drug development #Drug discovery #Drug targets #Immuno-oncology

Can this clinical trial move us closer to an Alzheimer’s treatment?

Exscientia has announced a Phase I clinical study of DSP-0038 in the US for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma… Read More

#News

#Clinical trial #Drug development #MS

‘Mega-trial’ for progressive multiple sclerosis (MS) to launch

Octopus, a world-first mega-trial for progressive multiple sclerosis (MS), will launch in the UK later in 2021, according to the MS Society. It is a clinical trial that is said will transform the way treatments for progressive MS are tested and could deliver new options up to three times faster. Read More

#News

#Clinical trial #Covid-19 #Data

Clinical trials impacted by slow enrolment

The surge in new variants for Covid-19 and an increase in subsequent cases is continuing to have an impact on clinical trials, while still allowing them to resume. The total number of disrupted trials has levelled off, but the number of clinical trials that have resumed continues to rise, although… Read More

#News

#Cancer research #Clinical trial

Lytix Biopharma announces positive Phase I data for LTX-315

Lytix Biopharma has announced promising full data results from a Phase I study of its lead candidate LTX-315 lysing solid tumours, which have been published in Clinical Cancer Research. The study was an open-label multicentre study of LTX-315 with multiple intralesional injections in patients with solid tumours for whom alternative… Read More

#Cancer Research #News

#Clinical trial #Clinical trials #Data #Sitting Down With

What has the pandemic taught us about clinical trials?

The latest DDW Sponsored Sitting Down With podcast features Raj Indupuri, CEO of eClinical Solutions, and he talks to us about clinical trials. Listen to this podcast to find out why Indupuri believes ‘data is the new fuel that will drive human progress’, the effect of Covid-19 on clinical trials… Read More

#Podcasts

#Clinical trial #Drug design #Drug development #Drug discovery #Research

Call to rethink “primitive” clinical trial approaches

Virtual clinical development specialist, Phesi, is calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analysed 330,000 clinical trials from the past 15 years and found the majority require substantial protocol amendments and… Read More

#News

#Clinical trial #Drug development #Drug discovery

MHRA authorises treatment to reduce the risk of cardiovascular events

Amarin Corporation has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established… Read More

#News